Biron Bethany M, Ayala Alfred, Lomas-Neira Joanne L
Division of Surgical Research, Department of Surgery, The Warren Alpert Medical School of Brown University/Rhode Island Hospital, Providence, RI, USA.
Biomark Insights. 2015 Sep 15;10(Suppl 4):7-17. doi: 10.4137/BMI.S29519. eCollection 2015.
Every year numerous individuals develop the morbid condition of sepsis. Therefore, novel biomarkers that might better inform clinicians treating such patients are sorely needed. Difficulty in identifying such markers is in part due to the complex heterogeneity of sepsis, resulting from the broad and vague definition of this state/condition based on numerous possible clinical signs and symptoms as well as an incomplete understanding of the underlying pathobiology of this complex condition. This review considers some of the attempts that have been made so far, looking at both the pro- and anti-inflammatory response to sepsis, as well as genomic analysis, as sources of potential biomarkers. Irrespective, for functional biomarker(s) of sepsis to successfully translate from the laboratory to a clinical setting, the biomarker must be target specific and sensitive as well as easy to implement/interpret, and be cost effective, such that they can be utilized routinely in patient diagnosis and treatment.
每年都有许多人患上脓毒症这种病态疾病。因此，迫切需要能够为治疗此类患者的临床医生提供更好信息的新型生物标志物。识别此类标志物的困难部分源于脓毒症复杂的异质性，这是由于基于众多可能的临床体征和症状对这种状态/病症的宽泛且模糊的定义，以及对这种复杂病症潜在病理生物学的不完全理解所致。本综述考虑了迄今为止所做的一些尝试，着眼于对脓毒症的促炎和抗炎反应以及基因组分析，将其作为潜在生物标志物的来源。无论如何，为了使脓毒症的功能性生物标志物能够成功地从实验室转化到临床环境中，该生物标志物必须具有靶点特异性、敏感性，易于实施/解读，并且具有成本效益，以便能够常规用于患者的诊断和治疗。
